Key facts
- This page summarizes Sumit Aggarwal's Form 4 filing for Eloxx Pharmaceuticals, Inc. (ELOX).
- 20 reported transactions and 16 derivative rows are listed below.
- Accepted by SEC: 08 May 2026, 16:53.
Sumit Aggarwal - 06 Feb 2022 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)
- Reporting relationship
- President and CEO, Director, 10%+ Owner
- Issuer ticker
- ELOX
- Reported as of
- 06 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 May 2026, 16:53:53 UTC
- Prior SEC filing
- 03 Dec 2021
- Next SEC filing
- 27 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sumit Aggarwal
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sumit Aggarwal filed Form 4 for Eloxx Pharmaceuticals, Inc. (ELOX) on 08 May 2026.
Change
- Previous filing in this sequence was filed on 03 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001854362
Primary reporting owner
Aggarwal Sumit
- Relationship
- President and CEO, Director, 10%+ Owner
- Address
- C/O ELOXX PHARMACEUTICALS, INC., P.O. BOX 274, ARLINGTON
- Signature
- /s/ Sumit Aggarwal
- Signature date
- 08 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELOX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +196,880
- Change %
- +98%
- Price
- $0.000100*
- Shares after
- 396,810
- Date
- 14 Aug 2025
- Ownership
- Direct
ELOX
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,000,000
- Change %
- +252%
- Price
- $0.000000*
- Shares after
- 1,396,810
- Date
- 19 Sep 2025
- Ownership
- Direct
- Footnotes
- F1
ELOX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +1.1%
- Price
- Shares after
- 1,411,810
- Date
- 24 Jan 2026
- Ownership
- Direct
- Footnotes
- F2
ELOX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +260,946
- Change %
- +18%
- Price
- $0.1500*
- Shares after
- 1,672,756
- Date
- 28 Feb 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +42,790
- Change %
- Price
- $0.000000*
- Shares after
- 42,790
- Date
- 06 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,790
- Exercise price
- $18.40
- Footnotes
- F3, F4
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -42,790
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,790
- Exercise price
- $18.40
- Footnotes
- F3, F4, F5
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +42,790
- Change %
- Price
- Shares after
- 42,790
- Date
- 16 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,790
- Exercise price
- $0.000100
- Footnotes
- F3, F5
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -35,580
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,580
- Exercise price
- $3.36
- Footnotes
- F4, F6, F7
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +35,580
- Change %
- Price
- Shares after
- 35,580
- Date
- 16 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,580
- Exercise price
- $0.000100
- Footnotes
- F6, F7
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -24,810
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,810
- Exercise price
- $1.41
- Footnotes
- F4, F6, F8
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +24,810
- Change %
- Price
- Shares after
- 24,810
- Date
- 16 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,810
- Exercise price
- $0.000100
- Footnotes
- F6, F8
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -68,700
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 68,700
- Exercise price
- $4.27
- Footnotes
- F9, F10
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +68,700
- Change %
- Price
- Shares after
- 68,700
- Date
- 16 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 68,700
- Exercise price
- $0.000100
- Footnotes
- F9, F10
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -60,390
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,390
- Exercise price
- $0.000100
- Footnotes
- F6
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -68,700
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 68,700
- Exercise price
- $0.000100
- Footnotes
- F9
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $0.000100
- Footnotes
- F11
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -42,790
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,790
- Exercise price
- $0.000100
- Footnotes
- F3
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +3,597,090
- Change %
- Price
- $0.000000*
- Shares after
- 3,597,090
- Date
- 19 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,597,090
- Exercise price
- $0.1500
- Footnotes
- F12
ELOX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -50%
- Price
- $0.000000*
- Shares after
- 15,000
- Date
- 24 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- Footnotes
- F2, F13
ELOX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -260,946
- Change %
- -7.3%
- Price
- $0.000000*
- Shares after
- 3,336,144
- Date
- 28 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 260,946
- Exercise price
- $0.1500
- Footnotes
- F12
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 13 footnotes
Footnote F1
Represents a grant of restricted stock units ("RSUs") that was fully vested upon grant.
Footnote F2
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.
Footnote F4
On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split.
Footnote F5
The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price.
Footnote F6
The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter.
Footnote F7
The reporting person agreed to cancellation of an option granted to him on April 1, 2021 in exchange for a new option having a lower exercise price.
Footnote F8
The reporting person agreed to cancellation of an option granted to him on May 18, 2021 in exchange for a new option having a lower exercise price.
Footnote F9
The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.
Footnote F10
The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price.
Footnote F11
The option was granted on August 23, 2023 and was scheduled to vest subject to certain performance criteria, which the Board waived in connection with the exercise.
Footnote F12
The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
Footnote F13
The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter.